Display options
Cite
Williams RM, Jaimes EA, Heller DA. Nanomedicines for kidney diseases. Kidney Int. 2016;90(4):740-5doi: 10.1016/j.kint.2016.03.041.
Williams, R. M., Jaimes, E. A., & Heller, D. A. (2016). Nanomedicines for kidney diseases. Kidney international, 90(4), 740-5. https://doi.org/10.1016/j.kint.2016.03.041
Williams, Ryan M, et al. "Nanomedicines for kidney diseases." Kidney international vol. 90,4 (2016): 740-5. doi: https://doi.org/10.1016/j.kint.2016.03.041
Williams RM, Jaimes EA, Heller DA. Nanomedicines for kidney diseases. Kidney Int. 2016 Oct;90(4):740-5. doi: 10.1016/j.kint.2016.03.041. Epub 2016 Jun 09. PMID: 27292222; PMCID: PMC5064150.
Copy Download .nbib Format: NLM
Share it on

Kidney Int. 2016 Oct;90(4):740-5. doi: 10.1016/j.kint.2016.03.041. Epub 2016 Jun 09.

Nanomedicines for kidney diseases.

Kidney international

Ryan M Williams, Edgar A Jaimes, Daniel A Heller

Affiliations

  1. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  2. Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: [email protected].
  3. Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, Cornell University, New York, NY, USA. Electronic address: [email protected].

PMID: 27292222 PMCID: PMC5064150 DOI: 10.1016/j.kint.2016.03.041

Abstract

Nanomedicines have been the subject of great interest for the treatment, diagnosis, and research of disease; however, few specifically address kidney disorders. Nanotechnology can confer significant benefits to medicine, such as the targeted delivery of drugs to specific tissues. Nanomedicines in the clinic have increased drug solubility, reduced off-target side effects, and provided novel diagnostic tools. There is an increasing cohort of nanomaterials that may have implications for kidney disease. Here, we review nanomaterial properties that are potentially applicable to kidney research and therapy, and we highlight clinical areas of need that may benefit from kidney nanomedicines.

Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Keywords: diagnostics; drug development; imaging; nanoparticles; theranostics; therapeutics

References

  1. Mol Aspects Med. 1994;15 Suppl:s257-63 - PubMed
  2. Adv Drug Deliv Rev. 2010 Nov 30;62(14):1344-57 - PubMed
  3. Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79 - PubMed
  4. Mol Pharm. 2011 Dec 5;8(6):2101-41 - PubMed
  5. Nanomedicine (Lond). 2012 May;7(5):639-50 - PubMed
  6. Theranostics. 2014 Aug 13;4(10):1039-51 - PubMed
  7. J Pharmacol Exp Ther. 2011 May;337(2):411-22 - PubMed
  8. J Am Soc Nephrol. 2008 Aug;19(8):1599-605 - PubMed
  9. J Magn Reson Imaging. 2004 Sep;20(3):512-8 - PubMed
  10. Int J Pharm. 2006 Jan 3;307(1):93-102 - PubMed
  11. Am J Physiol Renal Physiol. 2015 Apr 1;308(7):F765-73 - PubMed
  12. Nat Nanotechnol. 2007 Dec;2(12):751-60 - PubMed
  13. J Nanosci Nanotechnol. 2012 Jul;12(7):5149-54 - PubMed
  14. Annu Rev Med. 2012;63:185-98 - PubMed
  15. PLoS One. 2009 Aug 13;4(8):e6634 - PubMed
  16. Proc Natl Acad Sci U S A. 2012 Feb 21;109 (8):3137-42 - PubMed
  17. Theranostics. 2015 Jan 01;5(2):110-23 - PubMed
  18. Science. 2005 Jan 28;307(5709):538-44 - PubMed
  19. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6656-61 - PubMed
  20. Nat Rev Cancer. 2011 Dec 23;12(1):39-50 - PubMed
  21. Lancet Oncol. 2013 Jul;14(8):769-76 - PubMed
  22. Drug Deliv. 2016;23 (2):395-404 - PubMed
  23. Int J Nanomedicine. 2008;3(2):151-67 - PubMed
  24. Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93 - PubMed
  25. Cancer Treat Res. 2015;166:293-322 - PubMed
  26. J Microencapsul. 2016 Feb;33(1):30-42 - PubMed
  27. Int J Clin Exp Pathol. 2012;5(7):698-706 - PubMed
  28. Adv Chronic Kidney Dis. 2013 Nov;20(6):500-7 - PubMed
  29. Mol Pharmacol. 2007 Jul;72(1):121-31 - PubMed
  30. J Nanobiotechnology. 2015 Oct 24;13:75 - PubMed
  31. Magn Reson Med. 2008 Sep;60(3):564-74 - PubMed
  32. Br J Radiol. 2006 Mar;79(939):248-53 - PubMed
  33. J Am Soc Nephrol. 2010 Apr;21(4):622-33 - PubMed
  34. J Young Pharm. 2011 Jul;3(3):216-20 - PubMed
  35. PLoS One. 2013;8(1):e51992 - PubMed
  36. Nephron. 2001 Oct;89(2):194-200 - PubMed
  37. J Clin Invest. 2011 Nov;121(11):4210-21 - PubMed
  38. IET Nanobiotechnol. 2015 Dec;9(6):342-8 - PubMed
  39. Nano Lett. 2015 Apr 8;15(4):2358-64 - PubMed
  40. Exp Mol Pathol. 2009 Jun;86(3):215-23 - PubMed
  41. Free Radic Biol Med. 2014 Aug;73:299-307 - PubMed
  42. J Drug Target. 2012 Jul;20(6):535-43 - PubMed
  43. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Jan-Feb;6(1):40-60 - PubMed
  44. Nanotechnology. 2008 Dec 17;19(50):505101 - PubMed
  45. Nano Lett. 2008 Dec;8(12):4593-6 - PubMed
  46. Nano Lett. 2005 May;5(5):829-34 - PubMed
  47. Radiology. 2000 Dec;217(3):819-26 - PubMed
  48. Colloids Surf B Biointerfaces. 2014 Mar 1;115:286-94 - PubMed
  49. Nucleic Acid Ther. 2015 Apr;25(2):53-64 - PubMed
  50. Nat Biotechnol. 2007 Oct;25(10):1165-70 - PubMed
  51. Surg Clin North Am. 2007 Apr;87(2):353-64, viii - PubMed
  52. Am J Kidney Dis. 2016 Jun;67(6):984-8 - PubMed
  53. Mol Imaging. 2010 Dec;9(6):291-310 - PubMed
  54. Nephrol Dial Transplant. 2008 Oct;23(10):3234-9 - PubMed
  55. Basic Clin Pharmacol Toxicol. 2008 May;102(5):453-8 - PubMed
  56. ACS Nano. 2015 ;9(4):3641-53 - PubMed
  57. Cancer Lett. 2006 Jul 28;239(1):129-35 - PubMed
  58. Adv Drug Deliv Rev. 2008 May 22;60(8):863-75 - PubMed
  59. ACS Nano. 2015 Mar 24;9(3):2477-88 - PubMed
  60. Nat Nanotechnol. 2013 May;8(5):336-40 - PubMed
  61. Mater Sci Eng C Mater Biol Appl. 2014 Feb 1;35:153-63 - PubMed
  62. Hypertens Res. 2014 May;37(5):405-12 - PubMed
  63. J Control Release. 2012 Jun 10;160(2):117-34 - PubMed
  64. Eur J Pharm Sci. 2013 Feb 14;48(3):416-27 - PubMed
  65. Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12 - PubMed
  66. Eur J Pharm Biopharm. 2007 Sep;67(2):361-9 - PubMed
  67. Nat Nanotechnol. 2010 Nov;5(11):815-21 - PubMed

MeSH terms

Publication Types

Grant support